 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 August 1999 | Volume 131 Issue 3 | Pages 207-219
Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a biphasic or triphasic clinical course in which a benign chronic phase is followed by transformation into an accelerated and blastic phase. On a cytogenetic and molecular level, most patients with chronic myelogenous leukemia demonstrate BCR-ABL fusion genes in hematopoietic progenitor cells, which result from a reciprocal translocation between chromosomes 9 and 22; this translocation leads to a shortened chromosome 22, called the Philadelphia chromosome. Translation of the fusion products yields chimeric proteins of variable size that have increased tyrosinekinase activity. Conventional chemotherapy with hydroxyurea or busulfan can achieve hematologic control but cannot modify the natural disease course, which inevitably terminates in a rapidly fatal blastic phase. Since its introduction in the 1980s, allogeneic stem-cell transplantation has provided the groundwork for a cure of chronic myelogenous leukemia. However, few patients are eligible for this treatment because of donor availability and age restrictions. Therapy with interferon-
Author and Article Information
From the University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Requests for Reprints: Hagop M. Kantarjian, MD, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Current Author Addresses: Drs. Faderl and Kantarjian: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Drs. Talpaz and Estrov: Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030. REVIEW
Chronic Myelogenous Leukemia: Biology and Therapy
alone or in combination with cytarabine suppresses theleukemic clone, produces cytogenetic remissions, and prolongs survival. It is an effective alternative first-line treatment for patients ineligible for transplantation. New drugs active against chronic myelogenous leukemia may show increased activity in the transformed phases of the disease. Novel therapies and concepts are developing rapidly; targeted molecules are tyrosine kinases, ras, and messenger RNA through antisense oligonucleotides. Alternative transplantation options, such as stem cells from autologous sources and matched unrelated donors, are expanding. Immunomodulation by adoptive immunotherapy and vaccine strategies hold significant promise for the cure of chronic myelogenous leukemia.
This article has been cited by other articles:
|
|
 |
|
  J. Sessions Chronic myeloid leukemia in 2007 Am. J. Health Syst. Pharm., December 15, 2007; 64(24_Supplement_15): S4 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. A. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, A. M. Apanovitch, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood, October 1, 2007; 110(7): 2309 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Ann Intern Med, December 19, 2006; 145(12): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sessions Monitoring your patients with chronic myeloid leukemia. Am. J. Health Syst. Pharm., December 1, 2006; 63(23_Supplement_8): S5 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Aichberger, M. Mayerhofer, A. Vales, M.-T. Krauth, K. V. Gleixner, M. Bilban, H. Esterbauer, K. Sonneck, S. Florian, S. Derdak, et al. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells Blood, November 15, 2006; 108(10): 3538 - 3547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B. J. Druker, R. A. Larson, S. O'Brien, C. So, G. Massimini, and F. Guilhot Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials Blood, September 1, 2006; 108(5): 1478 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med., June 15, 2006; 354(24): 2542 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, C. L. Willman, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia PNAS, February 21, 2006; 103(8): 2794 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, H. Kantarjian, S. O'Brien, M. B. Rios, L. Abruzzo, S. Verstovsek, G. Garcia-Manero, and J. Cortes Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate Blood, January 15, 2006; 107(2): 480 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Parmar, J. Smith, A. Sassano, S. Uddin, E. Katsoulidis, B. Majchrzak, S. Kambhampati, E. A. Eklund, M. S. Tallman, E. N. Fish, et al. Differential regulation of the p70 S6 kinase pathway by interferon {alpha} (IFN{alpha}) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells Blood, October 1, 2005; 106(7): 2436 - 2443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Komarova and D. Wodarz Drug resistance in cancer: Principles of emergence and prevention PNAS, July 5, 2005; 102(27): 9714 - 9719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, R. Luthra, F. Giles, S. Verstovsek, S. Faderl, D. Thomas, G. Garcia-Manero, M. B. Rios, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} Blood, October 1, 2004; 104(7): 1979 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Parmar, E. Katsoulidis, A. Verma, Y. Li, A. Sassano, L. Lal, B. Majchrzak, F. Ravandi, M. S. Tallman, E. N. Fish, et al. Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells J. Biol. Chem., June 11, 2004; 279(24): 25345 - 25352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak, D. Thomas, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood, April 15, 2004; 103(8): 2873 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ali, F. Ozkalemkas, V. Ozkocaman, T. Ozcelik, U. Ozan, Y. Kimya, and A. Tunali Successful Pregnancy and Delivery in a Patient with Chronic Myelogenous Leukemia (CML), and Management of CML with Leukapheresis during Pregnancy: a Case Report and Review of the Literature Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 215 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gabriele, P. Borghi, C. Rozera, P. Sestili, M. Andreotti, A. Guarini, E. Montefusco, R. Foa, and F. Belardelli IFN-{alpha} promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment Blood, February 1, 2004; 103(3): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. La Rosee, K. Johnson, A. S. Corbin, E. P. Stoffregen, E. M. Moseson, S. Willis, M. M. Mauro, J. V. Melo, M. W. Deininger, and B. J. Druker In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines Blood, January 1, 2004; 103(1): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, F. Giles, S. O'Brien, D. Thomas, G. Garcia-Manero, M. B. Rios, S. Faderl, S. Verstovsek, A. Ferrajoli, E. J. Freireich, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome--positive chronic myeloid leukemia after failure of interferon-{alpha} Blood, July 1, 2003; 102(1): 83 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Cortes, M. Talpaz, F. Giles, S. O'Brien, M. B. Rios, J. Shan, G. Garcia-Manero, S. Faderl, D. A. Thomas, W. Wierda, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy Blood, May 15, 2003; 101(10): 3794 - 3800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, J. Cortes, S. O'Brien, S. Faderl, D. Thomas, F. Giles, M. B. Rios, J. Shan, and R. Arlinghaus Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia Clin. Cancer Res., January 1, 2003; 9(1): 160 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, F. Giles, G. Garcia-Manero, S. Faderl, D. Thomas, S. Jeha, M. B. Rios, L. Letvak, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses Blood, January 1, 2003; 101(1): 97 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Corbin, E. Buchdunger, F. Pascal, and B. J. Druker Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571 J. Biol. Chem., August 23, 2002; 277(35): 32214 - 32219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, S. O'Brien, J. E. Cortes, S. A. Giralt, M. B. Rios, J. Shan, F. J. Giles, D. A. Thomas, S. Faderl, M. De Lima, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia Blood, August 13, 2002; 100(5): 1590 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, S. O'Brien, J. E. Cortes, T. L. Smith, M. B. Rios, J. Shan, Y. Yang, F. J. Giles, D. A. Thomas, S. Faderl, et al. Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate Clin. Cancer Res., July 1, 2002; 8(7): 2167 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, M. Talpaz, S. O'Brien, T. L. Smith, F. J. Giles, S. Faderl, D. A. Thomas, G. Garcia-Manero, J.-P. J. Issa, M. Andreeff, et al. Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-{alpha}: Follow-Up Results Clin. Cancer Res., July 1, 2002; 8(7): 2177 - 2187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mc Gee, G. Campiani, A. Ramunno, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer Activation of the c-Jun N-terminal Kinase (JNK) Signaling Pathway Is Essential during PBOX-6-induced Apoptosis in Chronic Myelogenous Leukemia (CML) Cells J. Biol. Chem., May 17, 2002; 277(21): 18383 - 18389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Sawyers, A. Hochhaus, E. Feldman, J. M. Goldman, C. B. Miller, O. G. Ottmann, C. A. Schiffer, M. Talpaz, F. Guilhot, M. W. N. Deininger, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood, May 15, 2002; 99(10): 3530 - 3539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, J. Cortes, S. O'Brien, F. J. Giles, M. Albitar, M. B. Rios, J. Shan, S. Faderl, G. Garcia-Manero, D. A. Thomas, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase Blood, May 15, 2002; 99(10): 3547 - 3553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-I. Lee, H. Kantarjian, A. Glassman, M. Talpaz, and M.-S. Lee Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction Ann. Onc., May 1, 2002; 13(5): 781 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Countouriotis, T. B. Moore, and K. M. Sakamoto Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies Stem Cells, May 1, 2002; 20(3): 215 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Talpaz, R. T. Silver, B. J. Druker, J. M. Goldman, C. Gambacorti-Passerini, F. Guilhot, C. A. Schiffer, T. Fischer, M. W. N. Deininger, A. L. Lennard, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood, March 15, 2002; 99(6): 1928 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, et al. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia N. Engl. J. Med., February 28, 2002; 346(9): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Mauro, M. O'Dwyer, M. C. Heinrich, and B. J. Druker STI571: A Paradigm of New Agents for Cancer Therapeutics J. Clin. Oncol., January 1, 2002; 20(1): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bonifazi, A. de Vivo, G. Rosti, F. Guilhot, J. Guilhot, E. Trabacchi, R. Hehlmann, A. Hochhaus, P. C. A. Shepherd, J. L. Steegmann, et al. Chronic myeloid leukemia and interferon-alpha : a study of complete cytogenetic responders Blood, November 15, 2001; 98(10): 3074 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Donato, J. Y. Wu, L. Zhang, H. Kantarjian, and M. Talpaz Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor {beta}-chain in BCR-ABL+ human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition Blood, May 1, 2001; 97(9): 2846 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kano, M. Akutsu, S. Tsunoda, H. Mano, Y. Sato, Y. Honma, and Y. Furukawa In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood, April 1, 2001; 97(7): 1999 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nimmanapalli, E. O’Bryan, and K. Bhalla Geldanamycin and Its Analogue 17-Allylamino-17-demethoxygeldanamycin Lowers Bcr-Abl Levels and Induces Apoptosis and Differentiation of Bcr-Abl-positive Human Leukemic Blasts Cancer Res., March 1, 2001; 61(5): 1799 - 1804. [Abstract] [Full Text]
|
|
|
|
|
|
R. Nimmanapalli, M. Porosnicu, D. Nguyen, E. Worthington, E. O’Bryan, C. Perkins, and K. Bhalla Cotreatment with STI-571 Enhances Tumor Necrosis Factor {{alpha}}-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells Clin. Cancer Res., February 1, 2001; 7(2): 350 - 357. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. J. Druker, C. L. Sawyers, R. Capdeville, J. M. Ford, M. Baccarani, and J. M. Goldman Chronic Myelogenous Leukemia Hematology, January 1, 2001; 2001(1): 87 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, J. V. Melo, S. Tura, S. Giralt, and M. Talpaz Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies Hematology, January 1, 2000; 2000(1): 90 - 109. [Abstract] [Full Text] [PDF]
|
|
Article
